PDSB

PDS Biotechnology is a pre-revenue clinical-stage immunotherapy company whose value rests entirely on unproven pipeline assets — the Versamune platform, lead candidate PDS0101 (in combination with Keytruda), and PDS01ADC. Across FY2021–FY2025 it has never reported product revenue and has posted uninterrupted losses (-$16.9M, -$40.9M, -$42.9M, -$37.6M, -$34.5M), driving an accumulated deficit of -$217M. The FY2025 loss of -$34.5M did narrow (+8.3% YoY) and R&D fell -15.7% to $19.0M, but that is cost discipline in a company with nothing to sell, not evidence of a viable business. Return on equity of -154% and diluted EPS of -$0.74 confirm capital is being consumed, not compounded.

The balance sheet is the disqualifier. Cash of $26.7M (down -35.9% YoY) against operating cash burn of -$27.8M implies roughly one year of runway. Total assets fell -32.8% to $30.5M and equity dropped -39.9% to $22.4M, while shares outstanding grew +23.0% to 55.8M — the company is already funding itself by diluting holders, and with the stock at $0.85 any raise is deeply dilutive and comes as a sub-$1 price invites NASDAQ delisting pressure. A company this close to a funding cliff has essentially no margin for a clinical setback or a slow financing window.